Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Apr;43(4):972-4.
doi: 10.1128/AAC.43.4.972.

Pharmacokinetics of oral zidovudine entrapped in biodegradable nanospheres in rabbits

D P Callender  1 , N Jayaprakash, A Bell, V Petraitis, R Petraitiene, M Candelario, R Schaufele, J M Dunn, S Sei, T J Walsh, F M Balis
Affiliations

Pharmacokinetics of oral zidovudine entrapped in biodegradable nanospheres in rabbits

D P Callender et al. Antimicrob Agents Chemother. 1999 Apr.

Erratum in

  • Antimicrob Agents Chemother 1999 Dec;43(12):3046. Petratienes R [corrected to Petraitiene R]

Abstract

The pharmacokinetic profile of oral zidovudine entrapped in a 50:50 polyactide-coglycolide matrix (nanospheres) was compared to those of standard oral and parenteral zidovudine formulations in rabbits. The bioavailability of zidovudine nanospheres at 50 mg/kg of body weight was 76%, and this dose achieved prolonged exposure to zidovudine compared to standard formulations without an increase in the drug's peak concentration.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Plasma ZDV concentration-time profile for rabbits receiving 10 mg/kg i.v. (○) and 10 mg/kg orally in the conventional syrup formulation (□) (A), 10 mg/kg orally in the conventional syrup formulation (○) and entrapped in nanospheres with adjuvant (□) (B), or 10 mg/kg orally in the conventional syrup formulation (○) and 50 mg/kg orally entrapped in nanospheres with adjuvant (□) and without adjuvant (■) (C). Each point represents the mean of the plasma ZDV concentrations from three animals.
See this image and copyright information in PMC

References

    1. Abu-Izza K, Tambrallo L, Lu D R. In vivo evaluation of zidovudine (AZT)-loaded ethylcellulose microspheres after oral administration in beagle dogs. J Pharm Sci. 1997;86:554–559. - PubMed
    1. Abu-Izza K A, Garcia-Contreras L, Lu D R. Preparation and evaluation of sustained release AZT-loaded microspheres: optimization of the release characteristics using response surface methodology. J Pharm Sci. 1996;85:144–149. - PubMed
    1. Acosta E P, Page L M, Fletcher C V. Clinical pharmacokinetics of zidovudine, an update. Clin Pharmacokinet. 1996;30:251–262. - PubMed
    1. Balis F M, Pizzo P A, Eddy J, Wilfert C, McKinney R, Scott G, Murphy R F, Jarosinski P F, Falloon J, Poplack D G. The pharmacokinetics of azidothymidine administered intravenously and orally in children with human immunodeficiency virus infection. J Pediatr. 1989;114:880–884. - PubMed
    1. Balis F M, Pizzo P A, Murphy R F, Eddy J, Jarosinski P F, Falloon J, Broder , Poplack D G. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med. 1989;110:279–285. - PubMed

LinkOut - more resources